kabutan

HISAMITSU PHARMA, First Half Ordinary Profit Decreases by 6%

Thu Oct 9, 2025 3:30 pm JST Earnings

4530 HISAMITSU PHARMACEUTICAL CO.,INC. 【J-GAAP】

Earnings Report

HISAMITSU PHARMACEUTICAL CO.,INC. <4530> [TSE Prime] announced its financial results after the market closed on October 9th (15:30). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending February 2026 (March to August) decreased 6.5% from the same period last year to 10.0 billion yen. Progress toward the full-year plan of 24.3 billion yen was 41.5%, also falling below the five-year average of 52.0%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the September to February period (second half) is expected to grow 7.5% from the same period last year, reaching 14.2 billion yen.

In the most recent three-month period, from June to August (2Q), the consolidated ordinary profit grew 20.7% from the same period last year, reaching 6.30 billion yen. However, the operating profit margin decreased from 12.3% in the same period last year to 11.8%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Mar - Aug, 2023 66,977 8,396 11,640 8,417 108.3 59.2 Oct 6, 2023 J-GAAP
Mar - Aug, 2024 75,456 9,006 10,788 9,098 122.7 44.9 Oct 10, 2024 J-GAAP
Mar - Aug, 2025 74,943 8,128 10,089 7,022 97.0 41.5 Oct 9, 2025 J-GAAP
YoY -0.7% -9.7% -6.5% -22.8% -21.0%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar - Aug, 2025 Guidance ー ー ー ー － 60 Apr 10, 2025 J-GAAP
Mar - Aug, 2025 Results 74,943 8,128 10,089 7,022 97.0 60 Oct 9, 2025 J-GAAP
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Sep - Feb, 2024 80,550 9,889 13,222 12,660 172.0 45 Apr 10, 2025 J-GAAP
Sep - Feb, 2025 Guidance 90,057 11,872 14,211 14,978 214.0 60 Oct 9, 2025 J-GAAP
YoY +11.8% +20.1% +7.5% +18.3% +24.4%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Feb, 2024 141,706 13,167 19,649 13,969 181.6 85 Apr 11, 2024 J-GAAP
Feb, 2025 156,006 18,895 24,010 21,758 295.6 90 Apr 10, 2025 J-GAAP
Feb, 2026 Guidance 165,000 20,000 24,300 22,000 314.3 120 Apr 10, 2025 J-GAAP
YoY +5.8% +5.8% +1.2% +1.1% +6.3%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jun - Aug, 2024 39,646 4,857 5,226 4,310 58.1 12.3 Oct 10, 2024 J-GAAP
Sep - Nov, 2024 35,797 4,214 5,683 4,562 61.8 11.8 Jan 9, 2025 J-GAAP
Dec - Feb, 2024 44,753 5,675 7,539 8,098 110.0 12.7 Apr 10, 2025 J-GAAP
Mar - May, 2025 34,665 3,364 3,780 2,564 35.1 9.7 Jul 10, 2025 J-GAAP
Jun - Aug, 2025 40,278 4,764 6,309 4,458 61.6 11.8 Oct 9, 2025 J-GAAP
YoY +1.6% -1.9% +20.7% +3.4% +5.9%

Related Articles